Nonclinical toxicology development of a novel antibody antibiotic conjugate for treating invasive Staphylococcus Aureus infections

[1]  N. Lewin-Koh,et al.  Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: Longitudinal pharmacodynamic assessment by bioluminescence imaging , 2019, PloS one.

[2]  N. Lewin-Koh,et al.  A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers , 2019, Antimicrobial Agents and Chemotherapy.

[3]  W. Schaffner,et al.  Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs — Six Sites, 2005–2016 , 2018, MMWR. Morbidity and mortality weekly report.

[4]  S. Lehar,et al.  Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice , 2016, mAbs.

[5]  P. S. Andersen,et al.  Novel antibody–antibiotic conjugate eliminates intracellular S. aureus , 2015, Nature.

[6]  S. V. van Hal,et al.  Predictors of Mortality in Staphylococcus aureus Bacteremia , 2012, Clinical Microbiology Reviews.

[7]  W. Kelley,et al.  Staphylococcus aureus: new evidence for intracellular persistence. , 2009, Trends in microbiology.

[8]  J. Fraile,et al.  Endocarditis Caused by Staphylococcus aureus: A Reappraisal of the Epidemiologic, Clinical, and Pathologic Manifestations With Analysis of Factors Determining Outcome , 2009, Medicine.

[9]  M. Holdiness.  Teratology of the antituberculosis drugs. , 1987, Early human development.